Table 3.
Clinical characteristics of 396 patients with GBM with surgical resection classified according the RT delay
| Characteristics | ≤42 days, n (%) 206 (52.0) | >42 days, n (%) 190 (48.0) | P |
|---|---|---|---|
| Age (years)a | 59 (25–78) | 60 (20–80) | .92 |
| Sex | |||
| Male | 133 (64.6) | 120 (63.2) | .92 |
| Female | 73 (35.4) | 70 (36.8) | |
| Symptoms | |||
| Focal | 143 (69.1) | 116 (60.7) | .09 |
| Cognitive | 63 (30.6) | 63 (33.5) | .59 |
| Epilepsy | 48 (23.2) | 56 (29.3) | .17 |
| MRI location | |||
| Single lesion | 190 (92.2) | 174 (91.6) | .81 |
| Lobar | 166 (87.3) | 160 (91.9) | .19 |
| Surgery | |||
| Gross total resection | 122 (59.2) | 112 (59.0) | 1.00 |
| Partial resection | 84 (40.8) | 78 (41.0) | |
| Postoperative KPSa | 80 (100–50) | 80 (100–50) | .7 |
| 1st line chemotherapies | |||
| C-A TMZb | 180 (87.4) | 159 (83.7) | .23 |
| C-A TMZ + BCNU wafers | 18 (8.7) | 16 (8.4) | |
| BCNU wafersc | 8 (3.9) | 15 (7.9) | |
| 2nd line treatments | n = 160 | n = 155 | |
| Bevacizumab-based | 64 (40.0) | 62 (40.0) | .95 |
| Nitrosurea-based | 37 (23.1) | 35 (22.6) | |
| Radiosurgery | 7 (4.4) | 5 (3.2) | |
| Clinical Trials | 5 (3.1) | 6 (3.9) | |
| Palliative | 47 (29.4) | 47 (30.3) | |
aData expressed as median (range).
b22 patients also received bevacizumab or were included in clinical trials that tested bevacizumab or cilengitide.
c9 patients also received adjuvant TMZ. C-A TMZ: Concomitant and adjuvant temozolomide.